Overview

Study of Single and Multiple Doses of Inhaled AeroLEF (Liposome-Encapsulated Fentanyl)in Healthy Subjects

Status:
Completed
Trial end date:
2002-01-01
Target enrollment:
Participant gender:
Summary
This study was designed to assess single-dose and multiple-dose PK and safety parameters utilizing a dosage of 3 mL (500 µg/mL)AeroLEF delivered via nebulization with the AeroEclipse BAN device. The study was conducted in opioid naïve subjects who were not blocked with naloxone or other opioid receptor antagonists.
Phase:
Phase 1
Details
Lead Sponsor:
YM BioSciences
Treatments:
Fentanyl